BEGIN:VCALENDAR VERSION:2.0 PRODID:-//The BioCalendar - ECPv6.16.4//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:The BioCalendar X-ORIGINAL-URL:https://thebiocalendar.com X-WR-CALDESC:Events for The BioCalendar REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20270314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20271107T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20270314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20271107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260622T130000 DTEND;TZID=America/Los_Angeles:20260622T150000 DTSTAMP:20260617T051821 CREATED:20260507T200048Z LAST-MODIFIED:20260507T200048Z UID:10403-1782133200-1782140400@thebiocalendar.com SUMMARY:Venture Hub Showcase: International Pitch Event at BIO 2026 DESCRIPTION:Biocom is pleased to announce our upcoming Venture Hub Showcase—an international pitch event taking place during the 2026 BIO International Convention. This event offers a valuable opportunity to connect with potential strategic partners and investors\, while exploring the latest life science innovations from fellow industry leaders. Light snacks and refreshments will be provided. URL:https://thebiocalendar.com/event/venture-hub-showcase-international-pitch-event-at-bio-2026/ LOCATION:San Diego\, San Diego\, CA\, United States CATEGORIES:Presentation END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260622T110000 DTEND;TZID=America/Los_Angeles:20260622T120000 DTSTAMP:20260617T051821 CREATED:20260528T121901Z LAST-MODIFIED:20260528T121901Z UID:10536-1782126000-1782129600@thebiocalendar.com SUMMARY:Driving Faster Clinical Trial Setup: How Humans and AI Collaborate to Improve Quality\, Speed\, and Agility in Study Build DESCRIPTION:Study build inefficiency is rarely caused by a single failure point. Instead\, delays accumulate across fragmented protocol interpretation\, manual configuration\, iterative amendments\, and validation cycles that often surface issues late—when they are more costly to resolve. For many sponsors and CROs\, this has become the accepted baseline. The more important question is whether it needs to be. \nThis webinar explores how a more integrated human–AI collaboration model can address these challenges. Drawing on practical experience from study build environments\, we examine how AI can be applied not just to automate individual tasks\, but to support the full lifecycle—from protocol interpretation through configuration and validation. In this model\, AI contributes context-aware support grounded in clinical data structures and study design logic\, while clinical and operational experts guide decisions\, validate outputs\, and ensure regulatory alignment. \nWe will share how this approach is being implemented in practice\, including where AI can help reduce rework\, improve consistency in configuration\, and surface potential downstream issues earlier in the process. Particular focus will be given to how teams are balancing increased speed with the need for control\, auditability\, and quality. \nThrough real-world examples and live demonstration segments\, attendees will gain a practical understanding of how human expertise and AI can work together to improve study build performance—enabling faster timelines while maintaining rigor. \nWhy attend:\n– Gain a realistic\, experience-based perspective on AI in clinical operations\n– See how these approaches are being applied within active study environments\n– Understand how to improve speed without compromising quality or oversight URL:https://thebiocalendar.com/event/driving-faster-clinical-trial-setup-how-humans-and-ai-collaborate-to-improve-quality-speed-and-agility-in-study-build/ LOCATION:CA ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-22-26-Endpoint-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260622T110000 DTEND;TZID=America/Los_Angeles:20260622T120000 DTSTAMP:20260617T051821 CREATED:20260521T162343Z LAST-MODIFIED:20260522T081936Z UID:10504-1782126000-1782129600@thebiocalendar.com SUMMARY:From Variable to Predictable: How Intensified Upstream Processing Improves Scale-Up and Tech Transfer DESCRIPTION:As biomanufacturers face increasing pressure to boost productivity\, reduce costs\, and accelerate timelines\, traditional scale-up approaches can introduce variability and performance drift. Intensified upstream processing offers a more scalable\, efficient path forward—helping maintain product quality\, process stability\, and regulatory compliance from development through GMP manufacturing. \nIn this webinar\, Thermo Fisher Scientific experts share best practices and real-world insights on implementing intensified upstream strategies\, supported by advanced automation\, process analytical technologies (PAT)\, and data-driven control. \nIn this session\, you will learn how to:\n~ Drive productivity with intensification strategies\n~ Accelerate timelines using high-density inoculation and optimized seed trains\n~ Increase output through perfusion and hybrid processing models\n~ Improve consistency with automation\, PAT\, and real-time control\n~ Enable reliable scale-up with standardized tech transfer approaches \nKey challenges addressed:\n~ Performance drift and variability during scale-up\n~ Limited productivity with traditional processes\n~ Long development and seed train timelines\n~ Inconsistent results across sites \nDiscover how intensified upstream processing can help you scale with confidence while improving efficiency\, consistency\, and speed across your operations. URL:https://thebiocalendar.com/event/from-variable-to-predictable-how-intensified-upstream-processing-improves-scale-up-and-tech-transfer/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-22-26-Thermo-Reg-1920x250-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260621 DTEND;VALUE=DATE:20260622 DTSTAMP:20260617T051821 CREATED:20260501T115213Z LAST-MODIFIED:20260501T115213Z UID:10321-1782000000-1782086399@thebiocalendar.com SUMMARY:2026 SoCal TBA 10th Anniversary Symposium: AI\, Biotech & VC at UCLA DESCRIPTION:Celebrate 10 years of biotech innovation at UCLA. Explore the future of AI in medicine with VCs\, founders\, and industry leaders. \n\n\n\n\nFor the past decade\, SoCal TBA has connected the biotech communities of Southern California and Taiwan. This year’s theme\, “From Foundations to Frontiers: AI\, Innovation\, and the Future of Biomedicine\,” brings together leaders in venture capital\, biotech startups\, academia\, and industry to explore how AI is transforming the future of medicine. \nWhether you are a founder\, investor\, scientist\, student\, or biotech professional\, this symposium is designed to help you build relationships\, discover new ideas\, and stay ahead of where the industry is going next. URL:https://thebiocalendar.com/event/2026-socal-tba-10th-anniversary-symposium-ai-biotech-vc-at-ucla/ LOCATION:Los Angeles\, Los Angeles\, CA\, United States CATEGORIES:Symposium END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260618T130000 DTEND;TZID=America/Los_Angeles:20260618T190000 DTSTAMP:20260617T051821 CREATED:20260513T134910Z LAST-MODIFIED:20260513T134910Z UID:10443-1781787600-1781809200@thebiocalendar.com SUMMARY:Bases & Breakthroughs DESCRIPTION:A summer outing that actually does something. \nBases & Breakthroughs is built for teams. It’s an easy\, high-energy way for life science companies and supporters to invest in Philadelphia while giving employees\, clients\, partners\, and colleagues a memorable night out at the ballpark. \nYour ticket includes access to our pregame hospitality experience at Citizens Bank Park with ballpark eats and drinks\, plus seats together in our dedicated Life Science Cares section for Phillies vs. Mets. It’s casual\, social\, and designed for the region’s life sciences community to show up together. URL:https://thebiocalendar.com/event/bases-breakthroughs/ LOCATION:Philadelphia\, Philadelphia\, PA\, United States CATEGORIES:Social END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260618T110000 DTEND;TZID=America/Los_Angeles:20260618T120000 DTSTAMP:20260617T051821 CREATED:20260519T130313Z LAST-MODIFIED:20260522T082002Z UID:10457-1781780400-1781784000@thebiocalendar.com SUMMARY:Breaking the CLD Bottleneck: Generate Stable High-Producing Clones in 14 Weeks DESCRIPTION:Given its inherent time and resource demands\, variability in productivity\, and the rising complexity of monoclonal antibody (mAb) modalities—including bispecific antibodies (bsAb) and fusion proteins—cell line development (CLD) has become a leading constraint on bioprocess development. \nDesigned to address these constraints\, the Gibo™ CHOvantage™ GS CLD kit is a transposon-based CHO-K1 CLD platform that offers a solution for the accelerated production of stable\, high-performing cell lines. Using this platform\, mAb\, bsAb\, and Fc-fusion protein cell lines were generated in less than 14 weeks with high-titer pools consistently producing up to 5 g/L and corresponding stable clone titers reaching greater than 7 g/L. Selected clones were successfully scaled to bench scale and found to be stable in production and product quality for up to 100 generations. Collectively\, this demonstrates that the CHOvantage™ platform enables rapid\, robust\, and scalable generation of high-producing cell lines and represents an effective solution for accelerating biotherapeutic development. URL:https://thebiocalendar.com/event/breaking-the-cld-bottleneck-generate-stable-high-producing-clones-in-14-weeks/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-18-26-Thermo-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260618T110000 DTEND;TZID=America/Los_Angeles:20260618T120000 DTSTAMP:20260617T051821 CREATED:20260515T203642Z LAST-MODIFIED:20260526T212757Z UID:10445-1781780400-1781784000@thebiocalendar.com SUMMARY:When Art Meets Science: Creative Chromatography Solutions for Complex Small Molecules DESCRIPTION:Difficult to purify small molecules pose a big challenge for drug developers. Working with a CDMO that has specialized expertise in chromatography ensures that no matter the purification challenges or scale\, your program can be taken care of. Learn more… URL:https://thebiocalendar.com/event/when-art-meets-science-creative-chromatography-solutions-for-complex-small-molecules/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-18-26-MilliporeSigma-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260617T163000 DTEND;TZID=America/New_York:20260617T190000 DTSTAMP:20260617T051821 CREATED:20260611T183638Z LAST-MODIFIED:20260611T183638Z UID:10584-1781713800-1781722800@thebiocalendar.com SUMMARY:Beacon CoLab & BVS’ Biotech Connections: Vendor Showcase & Speaker Event\, Boston DESCRIPTION:We are very excited to invite you to the Beacon CoLab & BVS’ Biotech Connections: Vendor Showcase & Speaker Event in Boston! \nMark your calendars for a great opportunity to connect with industry leaders\, listen to engaging expert talks on AI\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe are inviting all research scientists from the institutes\, biotech/pharma\, and other companies in the Greater Boston to attend this event. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Industry Talks: Listen to two speakers on AI: Getting Past AI Fatigue — What’s Hype and What’s Real?\n Delicious Food & Drinks: Enjoy delicious food & refreshments as you network and explore the vendor exhibits. \nProgram: \n4:30 – 5:30 PM Registration & Vendor Exhibits \n5:30 – 6:30 PM Tech Talk: Getting Past AI Fatigue — What’s Hype and What’s Real? \nSpeakers: Sean Sanker Jr.\, Director of AI & Business Development\, Bay State IT and Jude Stiel\, Founder & CEO\, baobab.bio \nAI has been everywhere lately—but what’s actually delivering real value?\nIn this session\, experts will cut through the noise and share practical insights on what’s working today\, along with simple ways teams can start getting meaningful results from AI tools now. \n6:30 – 7:00 PM Networking\, Vendor Exhibits\, Drinks & Appetizers \nThis is a wonderful chance for everyone to come together\, share insights\, and celebrate the vibrant biotech landscape. \nAdmission Details: \n FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community who could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/beacon-colab-bvs-biotech-connections-vendor-showcase-speaker-event-boston/ LOCATION:CA ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/Beacon-CoLab-flyer-61726.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260617T130000 DTEND;TZID=America/Los_Angeles:20260617T140000 DTSTAMP:20260617T051821 CREATED:20260519T191928Z LAST-MODIFIED:20260522T082024Z UID:10493-1781701200-1781704800@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update June 2026: Antibody Drug Conjugates DESCRIPTION:In this Capabilities Update\, CDMOs will share how they support ADC programs from early development through clinical and commercial manufacturing. By attending this digital event\, you will gain insight into the technical expertise\, scalability\, and regulatory considerations required to advance ADCs efficiently. \nThe presentations will also highlight key considerations when evaluating CDMO partners\, including experience with complex conjugation processes and the ability to deliver integrated development and manufacturing support. \nWhether you are initiating a new ADC program or refining existing processes\, this session provides a clearer understanding of how to select a partner aligned with your program’s technical and operational needs. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-antibody-drug-conjugates/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-ADCs-scaled.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260617T110000 DTEND;TZID=America/Los_Angeles:20260617T120000 DTSTAMP:20260617T051821 CREATED:20260519T191814Z LAST-MODIFIED:20260522T082045Z UID:10489-1781694000-1781697600@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update June 2026: Microbial Development & Manufacturing DESCRIPTION:Join us for this digital event designed for pharmaceutical and biopharmaceutical companies seeking reliable CDMO partnerships to accelerate their microbial programs from development through commercial manufacturing. By attending this digital event\, you will learn how these capabilities come together to support efficient development\, smooth scale-up\, and consistent production. \nThe presentations will also provide insight into how experienced partners streamline timelines\, reduce risk\, and address the regulatory and quality considerations critical to successful program execution. \nWhether you are advancing early-stage research or preparing for commercial manufacturing\, you will gain practical guidance to help select a CDMO aligned with your technical\, quality\, and supply chain requirements. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-microbial-development-manufacturing/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-MICROBIAL-scaled.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260617T110000 DTEND;TZID=America/Los_Angeles:20260617T120000 DTSTAMP:20260617T051821 CREATED:20260519T124820Z LAST-MODIFIED:20260522T082112Z UID:10453-1781694000-1781697600@thebiocalendar.com SUMMARY:The True Science Behind eCOA\, Shaped By Patient and Site Insights DESCRIPTION:Clinical trials sit at a unique intersection of science\, patients\, and clinical care\, and for decades\, the “gold standard” has prioritized the rigor of the data\, often at the expense of the patients providing it. This gap between rigid protocol requirements and the realities of patients’ lives is a primary driver of participant hesitancy and high dropout rates. In eCOA\, where patient and site contributions are foundational to data quality\, this tension is especially consequential. Visit frequency\, required tasks\, and device flexibility all shape patient burden\, and these on-the-ground realities are too often absent from protocol design. \nThis webinar brings together patients\, sites\, and eCOA science to dismantle the researcher-subject hierarchy and replace it with a collaborative model. Through a panel discussion\, we’ll translate these perspectives into practical\, real-world insights to guide decisions within your protocol. This session aims to offer a more grounded blueprint for scientifically sound protocol design\, one where patient and site insights are embedded in the DNA of your eCOA strategy. \nKey Themes: \nThe Burden of Participation: Moving from “What data do we need?” to “How will this protocol impact a Tuesday afternoon for a single parent or a working professional?” and what trial design choices around eCOA follow from that shift. \nThe Site Lens: What sites observe firsthand when poor trial design translates to patient burden and operational friction \nTechnology as an Equalizer: How digital tools can reduce participation burden and improve data capture without creating a digital divide that excludes non-tech-savvy participants. \nDefining eCOA Science: What do we even mean by eCOA science? What might different stakeholders be thinking of with this term? And how does it differ from COA science? URL:https://thebiocalendar.com/event/the-true-science-behind-ecoa-shaped-by-patient-and-site-insights/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-17-26-Medidata-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260617T100000 DTEND;TZID=America/Los_Angeles:20260617T170000 DTSTAMP:20260617T051821 CREATED:20260501T115107Z LAST-MODIFIED:20260501T115107Z UID:10320-1781690400-1781715600@thebiocalendar.com SUMMARY:Bay Area Life Sciences & Biotech Conference DESCRIPTION:What You’ll Learn: \n\nGain insights into how renewed leasing activity\, selective capital and improving absorption are reshaping demand\, investment\, and development decisions across the Bay Area life sciences market.\nLearn how owners\, developers\, and operators are rethinking space utilization\, right sizing portfolios\, and repositioning existing assets to meet today’s tenant expectations.\nExamine why South San Francisco and the Peninsula continue to anchor regional growth and how emerging submarkets are positioning themselves to compete for talent and capital.\nGain insights into how architects\, engineers\, and builders are designing flexible\, scalable\, and technology enabled lab environments that can adapt to evolving research and operational needs.\nLearn how universities\, incubators\, and corporate partners are strengthening commercialization pipelines and supporting the next generation of biotech companies.\nGain insight into how AI\, automation\, and data analytics are transforming research workflows\, space management\, and building performance.\nHear the latest strategies for delivering sustainable\, electrified\, and high-performing lab facilities while balancing cost\, compliance\, and long-term value.\n\nHow You’ll Do More Business: After several years of market recalibration\, the Bay Area life sciences sector is entering a new phase defined by selective capital deployment\, shifting demand and location preferences\, and a renewed focus on high-quality\, future-ready assets. Join our full-day conference to hear from and connect with the region’s leading life sciences decision-makers\, capital partners\, developers\, and innovators. You’ll gain the insights\, relationships\, and deal-making opportunities needed to position your business for growth in the next chapter of the Bay Area life sciences market. \nWho You’ll Meet During Networking: Owners\, developers\, investors\, biotech tenants\, brokers\, city and government officials\, business consultants\, architects\, engineers\, lawyers\, accountants\, and bankers. \nWhy You Should Attend This Session: Bisnow events bring together the biggest power players in the industry to help you identify opportunities\, build your network\, and expand your business. With the largest audience of commercial real estate professionals in the world\, no one knows how to help your business more than we do. URL:https://thebiocalendar.com/event/bay-area-life-sciences-biotech-conference/ LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States CATEGORIES:Forum,Networking END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260616T130000 DTEND;TZID=America/Los_Angeles:20260616T140000 DTSTAMP:20260617T051821 CREATED:20260519T191645Z LAST-MODIFIED:20260522T082135Z UID:10485-1781614800-1781618400@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update June 2026: Cell Line Development DESCRIPTION:In this session\, leading CDMO experts will break down the key decisions across host cell selection\, vector design\, and clone screening strategies\, and explain how those choices impact expression\, scalability\, and long-term manufacturability. \nThese presentations will highlight how different CDMO approaches can reduce downstream risk or introduce it\, as programs move from early development into tech transfer and commercial readiness. \nIf you are advancing a monoclonal antibody\, recombinant protein\, or next-generation biologic\, this session will help clarify what to evaluate early—and what to avoid. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-cell-line-development/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-cell-line-scaled.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260616T110000 DTEND;TZID=America/Los_Angeles:20260616T120000 DTSTAMP:20260617T051821 CREATED:20260528T173411Z LAST-MODIFIED:20260528T173411Z UID:10549-1781607600-1781611200@thebiocalendar.com SUMMARY:The Levers And Tradeoffs That Drive Process Productivity DESCRIPTION:Increasing titers isn’t the only way to maximize process efficiency. Whether you’re optimizing an existing process or developing the next generation of biologics\, we can help you identify the levers that matter most. \nJoin us for an interactive discussion on the process decisions\, tradeoffs\, and operational realities shaping modern biologics manufacturing. Bioprocess Online’s Tyler Menichiello will moderate a conversation with two industry experts bringing firsthand experience in process development and biopharmaceutical manufacturing: \n• David Scherr\, Ph.D.\, Senior Scientist\, Bioprocessing Technologies and Engineering at AstraZeneca\n• Vadim Klyushnichenko\, Ph.D.\, VP\, Biopharmaceutical Development and Quality at Calibr-Skaggs Institute for Innovative Medicines \nScherr and Klyushnichenko will discuss where productivity gains are actually achieved and how teams are finding success by simplifying purification strategies and reducing chromatography steps. They will also explore how less obvious constraints (e.g.\, developability and facility fit) can shape productivity early and how complex molecules like bispecifics are redefining what process efficiency looks like. \nReserve your spot today. URL:https://thebiocalendar.com/event/the-levers-and-tradeoffs-that-drive-process-productivity/ LOCATION:CA ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/26_06-BPOL-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260616T110000 DTEND;TZID=America/Los_Angeles:20260616T120000 DTSTAMP:20260617T051821 CREATED:20260519T191458Z LAST-MODIFIED:20260522T082159Z UID:10481-1781607600-1781611200@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update June 2026: Cell Therapy DESCRIPTION:In this session\, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing\, scale-up\, and commercial readiness—and where different approaches can reduce downstream risk or introduce it. \nThis is a focused look at who does what\, and where they fit—so you can evaluate partners with greater clarity and move forward with more confidence. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-cell-therapy/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-CELL-THERAPY-scaled.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260615T110000 DTEND;TZID=America/Los_Angeles:20260615T120000 DTSTAMP:20260617T051821 CREATED:20260519T190644Z LAST-MODIFIED:20260522T082236Z UID:10473-1781521200-1781524800@thebiocalendar.com SUMMARY:Solving Formulation Challenges Across Modalities: Patient-Centric Nanoparticle Approaches for Small and Large Molecules DESCRIPTION:Explore how advanced nanoparticle engineering is transforming formulation across both small and large molecule modalities. Dr. Chris Worrall highlights how Nanoform’s technologies enable higher drug‑loading oral tablets\, ultra‑high‑concentration biologic formulations for SubQ delivery\, and new possibilities for pulmonary administration. Through real case studies\, you’ll see how nanoforming can reduce pill burden\, unlock patient‑friendly alternatives to IV infusion\, and improve therapeutic performance across modalities. \nKey learning objectives:\n– Overview of Nanoform’s Innovative Small and Large Molecule Nanoforming Technology Platforms to enable patient centric dosage forms\n– Case studies showcasing reduction in pill size and overall pill burden whilst maintaining exposure of supersaturating ASDs\n– A review of alternative dosage forms to IV infusions for large molecule therapeutics URL:https://thebiocalendar.com/event/solving-formulation-challenges-across-modalities-patient-centric-nanoparticle-approaches-for-small-and-large-molecules/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-15-26-Nanoform-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260614 DTEND;VALUE=DATE:20260619 DTSTAMP:20260617T051821 CREATED:20260316T091256Z LAST-MODIFIED:20260316T091256Z UID:10024-1781395200-1781827199@thebiocalendar.com SUMMARY:DIA 2026 Global Annual Meeting DESCRIPTION:The DIA Global Annual Meeting is where life sciences professionals from industry\, regulatory agencies\, patients\, and academia come together to drive breakthroughs in healthcare — advancing science\, policy\, and patient outcomes worldwide. URL:https://thebiocalendar.com/event/dia-2026-global-annual-meeting/ LOCATION:Philadelphia\, Philadelphia\, PA\, United States CATEGORIES:Annual Meeting END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260611T160000 DTEND;TZID=America/New_York:20260611T183000 DTSTAMP:20260617T051821 CREATED:20260507T161956Z LAST-MODIFIED:20260522T082334Z UID:10397-1781193600-1781202600@thebiocalendar.com SUMMARY:BVS\, in collaboration with JLL: Biotech Community Innovation Night at 115 Munson\, New Haven DESCRIPTION:We are very excited to invite you to our BVS\, in collaboration with JLL Biotech Community Innovation Night at 115 Munson! \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe are inviting all research scientists from the institutes\, biotech and other companies in New Haven and surrounding areas to attend this event. \n✨ What to Expect: \nVendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\nNetworking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\nBuilding Tours: Building tours of available space are available upon request.\nDelicious Food & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits. \nAdmission Details: \n– FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions\,etc.) from life science companies and research institutes.\n– $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-biotech-community-innovation-night-at-115-munson-new-haven-4/ LOCATION:CA CATEGORIES:Expo,Trade Show ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/05/BVS-Biotech-Event-Flyer-06-11-26.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260611T110000 DTEND;TZID=America/Los_Angeles:20260611T120000 DTSTAMP:20260617T051821 CREATED:20260520T185631Z LAST-MODIFIED:20260522T082358Z UID:10499-1781175600-1781179200@thebiocalendar.com SUMMARY:Using Residual DNA Quantification Data to De-risk mAb Development DESCRIPTION:IND submission is a critical milestone in mAb development — but analytical methods established at this stage must ultimately support validation\, tech transfer\, and evolving regulatory expectations. Among these\, residual host cell DNA quantitation assays play a central role in monitoring residual impurity levels\, supporting process performance\, and may help reduce downstream risks. \nThis webinar will position residual DNA quantitation not as an isolated assay\, but as a dataset that can be applied across downstream process intermediates to inform decision-making. Using data generated from protein-rich samples\, we will explore how assay sensitivity\, recovery\, and reproducibility perform under realistic manufacturing conditions\, including high IgG matrices. \nThrough practical examples\, attendees will see how residual DNA measurements can be used to compare purification performance across unit operations\, identify potential clearance risks early\, and support development of scalable\, validation-ready processes. The session will also highlight how sample composition and process conditions influence data interpretation\, reinforcing the importance of designing assays that remain robust as workflows evolve. \nLearning objectives: \n~ Evaluate how residual host cell DNA quantitation can be used to assess impurity clearance across downstream mAb process steps\n~ Interpret residual DNA data generated from complex\, protein-rich matrices to support process decision-making\n~ Identify key performance characteristics (e.g.\, sensitivity\, recovery\, reproducibility) required for validation-ready residual DNA assays\n~ Apply strategies for designing residual DNA workflows that remain robust and scalable from development through manufacturing URL:https://thebiocalendar.com/event/using-residual-dna-quantification-data-to-de-risk-mab-development/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-11-26-Thermo-Reg-1920x250-0.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260610T110000 DTEND;TZID=America/Los_Angeles:20260610T120000 DTSTAMP:20260617T051821 CREATED:20260519T191159Z LAST-MODIFIED:20260522T082428Z UID:10477-1781089200-1781092800@thebiocalendar.com SUMMARY:Viral Safety Testing in Biologics: Detecting What Current Methods Miss DESCRIPTION:This webinar breaks down how evolving expectations under ICH Q5A(R2) are reshaping viral detection strategies\, shifting the industry from targeted testing toward broader\, more sensitive approaches. Through real‑world examples\, you’ll learn where current methods fall short\, how newer technologies expand visibility\, and how teams can strengthen viral safety programs without disrupting development timelines or regulatory alignment. \nWatch the discussion to learn how to modernize viral safety testing and uncover what traditional methods may be missing. URL:https://thebiocalendar.com/event/viral-safety-testing-in-biologics-detecting-what-current-methods-miss/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-10-26-Minaris-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260609T110000 DTEND;TZID=America/Los_Angeles:20260609T120000 DTSTAMP:20260617T051821 CREATED:20260519T185932Z LAST-MODIFIED:20260522T082449Z UID:10469-1781002800-1781006400@thebiocalendar.com SUMMARY:Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs DESCRIPTION:In this webinar\, Lonza experts share insights from 70+ bispecific programs\, revealing the most common early‑stage risks across analytical development\, downstream purification\, and drug product formulation. You’ll learn where challenges typically emerge before IND\, how early decisions shape CMC readiness\, and when to rely on platform approaches versus molecule‑specific strategies to avoid costly delays. \nKey Learning Objectives:\n– Identify where development risks matter most before IND and what early stage challenges bispecific antibody programs most commonly run into\n– Understand how early analytical\, downstream\, and drug product formulation decisions can either accelerate progress or create downstream CMC and IND readiness challenges\n– Learn how Lonza balances speed and risk by knowing when platform approaches are sufficient and when molecule specific strategies are needed to avoid costly surprises URL:https://thebiocalendar.com/event/cracking-complexity-learnings-from-70-bispecific-antibody-programs/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-09-26-Lonza-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260606 DTEND;VALUE=DATE:20260611 DTSTAMP:20260617T051821 CREATED:20260504T221047Z LAST-MODIFIED:20260504T221047Z UID:10330-1780704000-1781135999@thebiocalendar.com SUMMARY:CYTO 2026 DESCRIPTION:CYTO 2026\, the 39th annual Congress of the International Society for the Advancement of Cytometry\, is the premier\, inclusive\, and international conference on the many facets of cytometry science and engineering. Guided by this year’s theme\, Cytometry: The Next Wave\, the meeting will showcase groundbreaking innovations and emerging directions shaping the field. Join us in West Palm Beach\, Florida—a destination celebrated for its year-round sunshine\, beautiful beaches\, vibrant arts scene\, and welcoming community. Home to a growing life sciences ecosystem\, anchored by leading biomedical research institutes\, innovative biotech companies\, and renowned medical centers\, this unique blend of community spirit and scientific innovation makes West Palm Beach the ideal setting for charting the next wave of cytometry at CYTO 2026. URL:https://thebiocalendar.com/event/cyto-2026/ LOCATION:West Palm Beach\, West Palm Beach\, FL\, United States CATEGORIES:Academic Research,Forum END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260604T160000 DTEND;TZID=America/New_York:20260604T183000 DTSTAMP:20260617T051821 CREATED:20260430T154259Z LAST-MODIFIED:20260522T082523Z UID:10312-1780588800-1780597800@thebiocalendar.com SUMMARY:BVS' Summer Biotech Community Celebration at Tech Square\, Cambridge DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at Tech Square. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nAll the biotech tenants at 100-700 Technology Square and other companies in the Cambridge vicinity are invited to attend this event. \n✨ What to Expect: \nVendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\nNetworking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\nDelicious Food & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits. \nAdmission Details: \nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions\,etc.) from life science companies and research institutes.\n$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-summer-biotech-community-celebration-at-tech-square-cambridge-3/ LOCATION:Cambridge\, MA\, Cambridge\, MA\, 02139\, United States CATEGORIES:Expo,Networking ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-06-04-26.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T110000 DTEND;TZID=America/Los_Angeles:20260604T120000 DTSTAMP:20260617T051821 CREATED:20260512T142112Z LAST-MODIFIED:20260522T082550Z UID:10436-1780570800-1780574400@thebiocalendar.com SUMMARY:Beyond Data Packages: Derisking Tech Transfer To CDMOs DESCRIPTION:Technology transfer to a CDMO is rarely as simple as handing over a data package. From documentation gaps and equipment differences to method variability and global standards\, many programs encounter avoidable risks that can derail timelines and increase cost. In this Outsourced Pharma Live session\, industry experts share practical strategies to help sponsors better prepare for tech transfer and align more effectively with CDMO partners. \nJoin us to learn how tools like smarter documentation systems\, design of experiments\, and in silico modeling can support stronger CMC alignment and improve the likelihood of a right-first-time transfer—across small molecules\, biologics\, and advanced therapies. URL:https://thebiocalendar.com/event/beyond-data-packages-derisking-tech-transfer-to-cdmos/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/26_06-OPL-HTML-600x300-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T110000 DTEND;TZID=America/Los_Angeles:20260604T120000 DTSTAMP:20260617T051821 CREATED:20260506T133246Z LAST-MODIFIED:20260522T082619Z UID:10374-1780570800-1780574400@thebiocalendar.com SUMMARY:Helping ensure safer immunotherapies: From gene editing to next-generation sequencing (NGS)-based T cell characterization DESCRIPTION:Immune checkpoint inhibitors have transformed cancer treatment\, but response rates remain limited\, and immune-related toxicities continue to pose challenges. Gene editing of therapeutic T cells offers a promising path to help enhance specificity and safety by directly modulating checkpoint expression. \nIn this webinar\, we explore how gene-edited T cells targeting PD-1 and TIGIT can improve anti-tumor activity\, based on preclinical models and ongoing translational research. We will present how tumor-infiltrating lymphocytes (TILs) derived from melanoma metastases are engineered\, expanded and functionally characterized to assess their therapeutic potential. \nBeyond the biology\, this session highlights the critical role of integrated genomic workflows in enabling these insights. From high-quality nucleic acid extraction to next-generation sequencing (NGS)-based transcriptomic profiling\, we highlight how automated\, high-throughput sample preparation and NGS downstream analysis enable reliable identification of gene expression changes driving T cell function and efficacy. \nJoin us to learn how combining advanced cell engineering with end-to-end genomic solutions can accelerate cell therapy discovery and lead selection\, bridging the gap between experimental design and actionable insight. \nLearning objectives:\n~ Understand how gene editing of immune checkpoints (PD-1\, TIGIT) can enhance T cell–based cancer therapies\n~ Learn how integrated workflows\, from automated\, high-throughput nucleic acid extraction to NGS\, enable high-quality\, reproducible transcriptomic insights\n~ Discover how genomic data can inform functional characterization and support cell therapy\, lead discovery and development URL:https://thebiocalendar.com/event/helping-ensure-safer-immunotherapies-from-gene-editing-to-next-generation-sequencing-ngs-based-t-cell-characterization/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-04-26-Qiagen-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T110000 DTEND;TZID=America/Los_Angeles:20260604T120000 DTSTAMP:20260617T051821 CREATED:20260417T125838Z LAST-MODIFIED:20260522T082702Z UID:10226-1780570800-1780574400@thebiocalendar.com SUMMARY:Supporting Efficient mAb Development with a Flexible Downstream Purification Toolkit DESCRIPTION:Bringing innovative antibody therapeutics to market quickly requires more than upstream efficiency. It demands adaptable and robust downstream purification strategies. \nAs novel mAb formats increase in complexity\, purification challenges grow. Achieving required purity and yield often extends beyond traditional 2–3 step platform processes\, requiring expanded chromatography options and optimized buffer systems. \nIn this webinar\, we will discuss: \n– Practical strategies for designing a flexible downstream purification toolkit\n– Approaches to buffer optimization for challenging antibody molecules\n– Ways to streamline process development while maintaining performance \nRegister to learn how a well-designed purification toolkit can help accelerate development timelines and improve process robustness. URL:https://thebiocalendar.com/event/supporting-efficient-mab-development-with-a-flexible-downstream-purification-toolkit/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/06-04-26-Thermo-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T080000 DTEND;TZID=America/Los_Angeles:20260604T160000 DTSTAMP:20260617T051821 CREATED:20260521T154458Z LAST-MODIFIED:20260521T154519Z UID:10503-1780560000-1780588800@thebiocalendar.com SUMMARY:2026 Life Sciences Workforce Conference DESCRIPTION:MassBioEd’s Annual Life Science Workforce Conference brings together representatives from the life sciences industry\, academic institutions\, training providers\, government and community to explore key issues and strategies in building a strong life science workforce in Massachusetts. \nThe 2026 Life Sciences Workforce Conference: Building Talent Pathways in a Dynamic Time: Massachusetts Prepares the Future Workforce will be held on \nJune 4th at Boston University URL:https://thebiocalendar.com/event/2026-life-sciences-workforce-conference/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Networking,Symposium END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260604 DTEND;VALUE=DATE:20260606 DTSTAMP:20260617T051821 CREATED:20260527T225156Z LAST-MODIFIED:20260527T225156Z UID:10521-1780531200-1780703999@thebiocalendar.com SUMMARY:Medical Device & Digital Health Conference DESCRIPTION:Join us for our 33rd Annual MDC\, which features engaging panel sessions and keynote addresses\, a Partnering Hall connecting attendees with start-ups and investors from around the globe\, the MedTech Innovator pitch event\, and a lively wine tasting reception where venture capitalists serve as sommeliers. URL:https://thebiocalendar.com/event/medical-device-digital-health-conference/ LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260604 DTEND;VALUE=DATE:20260606 DTSTAMP:20260617T051821 CREATED:20260501T115308Z LAST-MODIFIED:20260501T115308Z UID:10322-1780531200-1780703999@thebiocalendar.com SUMMARY:NYC AI x Longevity Summit DESCRIPTION:Dive into the future of aging with cutting-edge AI breakthroughs at this can’t-miss summit! \n\n\n\n\nJune 4–5\, 2026 | BioLabs@NYU Langone\, Long Island City\, Queens \nLongevity science is at an inflection point. Foundation models are learning the language of biology\, aging clocks are quantifying human health with new precision\, and a generation of therapeutics and clinical platforms is emerging to act on those signals. \nThe inaugural theme of the Summit\, Signal to Intervention\, explores how AI is compressing the distance between discovery and real-world impact. \nAs a flagship event of Longevity Global NYC\, the AI x Longevity Summit convenes the researchers\, clinicians\, founders\, and engineers building the next generation of longevity infrastructure. Hosted at BioLabs@NYU Langone in the heart of the city’s biotech corridor\, the Summit is where technical depth meets translational ambition. URL:https://thebiocalendar.com/event/nyc-ai-x-longevity-summit/ LOCATION:New York\, New York\, NY\, United States CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260603T110000 DTEND;TZID=America/Los_Angeles:20260603T120000 DTSTAMP:20260617T051821 CREATED:20260512T141741Z LAST-MODIFIED:20260522T082729Z UID:10432-1780484400-1780488000@thebiocalendar.com SUMMARY:Faster Clones\, Simpler Process: What’s Changing in CHO Expression? DESCRIPTION:CHO expression continues to evolve\, and recent advances are reshaping how quickly and efficiently high-performing cell lines are developed. In this webinar\, experts explore the latest innovations in the GS® Expression System\, highlighting how advanced vector design\, stronger selection stringency\, and enhanced promoter control are driving higher titers\, more stable pools\, and faster timelines from DNA to lead clone. \nKey Learning Objectives:\n– Understand the critical design elements of CHO expression vectors\n– Explore the development and performance advantages of improved glutamine synthetase selection stringency\n– Discover emerging data driven strategies for improving gene expression control in CHO cells URL:https://thebiocalendar.com/event/faster-clones-simpler-process-whats-changing-in-cho-expression-2/ LOCATION:Online webinar CATEGORIES:Webinar ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-03-26-Lonza-eblast-700x200-2.png END:VEVENT END:VCALENDAR